JP Morgan Private Capital, JP Morgan’s venture capital and growth equity investment team has held the final close of 270 Life Sciences Private Capital Fund I, above its $500m target.
LSPCF received commitments from institutional allocators, strategic corporate partners, family offices and HNWIs across North America, Europe, the Middle East and Asia, as well as JPMorgan Chase & Co. The fund close was led by CIO Stephen Squinto and Managing Partner Gaurav Gupta.
LSPCF invests in private biotechnology companies spanning cardiometabolic disease, oncology, immunology and genetic medicines.
Source:Private Equity Wire
Can’t stop reading? Read more
CapVest-backed IPN acquires premium pet food producer Sopral from Parquest
CapVest-backed IPN acquires premium pet food producer Sopral from Parquest CapVest Partners has...
Coller Capital secures record $6.8bn for private credit secondaries fund
Coller Capital secures record $6.8bn for private credit secondaries fund Coller Capital has closed...
Ardian exits landmark Paris asset following successful repositioning strategy
Ardian exits landmark Paris asset following successful repositioning strategy Ardian has completed...
